Esperion's (ESPR) Drugs Get EU Nod for Lowering Heart Risk

Esperion Therapeutics, Inc. (ESPR) and partner Daiichi Sankyo Europe GmbH announced that the European Commission (EC) has approved a label update for its drugs Nilemdo (bempedoic acid) and Nustendi for the treatment of hypercholesterolemia and to reduce the risk of adverse cardiovascular (CV) events. Hypercholesterolemia indicates elevated levels of cholesterol in the blood. Following the label expansion in Europe, Nilemdo and Nustendi became the first and only treatments for lowering low-density lipoprotei ...